Systemic Lupus Erythematosus - Clinical Aspects II

Session Type: ACR Abstract Submissions
Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Papers:
Clinical and Laboratory Correlates in Responders (by the Systemic Lupus Erythematosus Responder Index) in Phase 3 Belimumab Clinical Trials
R.A. Furie1, Z.J. Zhong2, W. Freimuth2 and M. Petri3, 1North Shore-LIJ Health System, Lake Success, NY, 2Human Genome Sciences, Inc., Rockville, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD
Retrospective Validation of the 3 Laboratory Organ Systems of Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Responder Index (SRI-50) Over 10 Years
Zahi Touma1, Dafna D. Gladman2, Dominique Ibanez1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON
Responders in the Phase 3 Belimumab Clinical Trials in Patients with Systemic Lupus Erythematosus Reported Improvements in Fatigue and Health-Related Quality of Life At Week 52
V. Strand1, S. Cooper2, Z.J. Zhong2 and G. Dennis2, 1Stanford University, Palo Alto, CA, 2Human Genome Sciences, Inc., Rockville, MD
Early Systemic Lupus Erythematosus Specific Antigens Predict Disease Characteristics
Jessica J. Hale1, Jennifer A. Kelly1, Chee Paul Lin1, Stuart B. Glenn1, Jourdan Anderson1, Patrick M. Gaffney2, Kathy L. Moser2, John B. Harley3, Judith A. James4 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK
Inefficient Strategic Planning with Compensatory Recruitment of Neural Pathway for Conflict Processing and Error Detection Despite Sufficient Disease Control in Patients with New Onset Systemic Lupus Erythematosus: A Prospective Functional MRI Study
Anselm Mak1, Tao Ren2, Erin Hui yun Fu1, Alicia AC Cheak1 and Roger CM Ho1, 1National University of Singapore, Singapore, Singapore, 2National University of Singapore, Sinagpore, Singapore
The Effects of Smoking on Age of Onset, Autoantibodies and Interferon- α in Systemic Lupus Erythematosus
Kimberly Smith, Stephanie L. Green, Daniel F. Brandt, Beverly S. Franek, Timothy B. Niewold and Tammy O. Utset, University of Chicago, Chicago, IL
25-Hydroxyvitamin D Levels Are Inversely Correlated with Systemic Lupus Erythematosus Disease Activity Index, but Are Not Associated with Relapse-Free Survival During Six Months Follow-up of 171 Patients Included in a French Prospective Multicentric Cohor
Yoland Schoindre1, Moez Jallouli2, Benjamin Terrier3, Marie-Laure Tanguy2, Zahir Amoura2, Jean-Charles Piette2, Patrice Cacoub2, Jean-Claude Souberbielle4, Nathalie Costedoat-Chalumeau2 and The group PLUS5, 1Foch Hospital, Suresnes, France, 2CHU Pitié-Salpêtrière, Paris, France, 3Pitié-Salpêtrière Hospital, Paris, France, 4CHU Necker, Paris, France, 5Paris
Association of Discoid Lupus with Clinical Manifestations and Damage Accrual in PROFILE: A Multiethnic Lupus Cohort
Yesenia C. Santiago-Casas1, Luis M. Vila1, G. McGwin Jr.2, Michelle Petri3, Rosalind Ramsey-Goldman4, John D. Reveille5, Robert P. Kimberly2, Graciela S. Alarcon2 and Elizabeth E. Brown6, 1University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2University of Alabama at Birmingham, Birmingham, AL, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5University of Texas Health Science Center at Houston, Houston, TX, 6Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Anti-C1q Antibody in Systemic Lupus Erythematosus
Ana-Maria Orbai1, Gunnar K. Sturfelt2, Ola Nived3, Hong Fang1, Graciela S. Alarcón4, Caroline Gordon5, Joan T. Merrill6, Paul R. Fortin7, Ian N. Bruce8, David A. Isenberg9, Daniel J. Wallace10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University Hospital Lund, Lund, Sweden, 3University Hospital, Lund, Sweden, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Birmingham, Birmingham, United Kingdom, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Toronto Western Hospital, Toronto, ON, 8A, Manchester, United Kingdom, 9University College London, London, United Kingdom, 10Cedars-Sinai/UCLA, Los Angeles, CA, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago
Comparison of Health-Related Quality of Life, Disease Damage, Disability, Age and Disease Duration in Pediatric Lupus Across Different Continents: An Expanded Sample
Lakshmi N. Moorthy, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, NJ and the International SMILEY Collaboprative Group, New Brunswick
Systemic Lupus Erythematosus (SLE) and Vitamin D (Vit D) Deficiency Are Associated with Shorter Telomere Length
Brett M. Hoffecker1, Laura M. Tonks2, Tamara K. Nowling1 and Diane L. Kamen1, 1Medical University of SC, Charleston, SC, 2UNC Chapel Hill, NC
Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus
Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Marilyn C. Pike, Med Pharm Consulting Inc, Cambridge, MA, Lexy Kelley, UCB, Smyrna, GA, Brian Kilgallen, UCB, Brussels, Belgium and Caroline Gordon, Medical School, Birmingham, United Kingdom
Corticosteroid Use and Associated Risk of Adverse Events in Patients with Systemic Lupus Erythematosus: A Retrospective Claims Analysis
Manan Shah1, Sham Chaudhari1, Trent McLaughlin1, Hong Kan2, Benno Bechtel3 and Charles T. Molta4, 1Xcenda, LLC, Palm Harbor, FL, 2GlaxoSmithKline, Research Triangle Park, NC, 3GlaxoSmithKline, Munich, Germany, 4GlaxoSmithKline, Philadelphia, PA
Prevalence and Associated Factors for Asymptomatic Pulmonary Arterial Hypertension in Patients with Systemic Lupus Erythematosus
Ki-Jo Kim1, Ji-Young Kim2, Su-Jung Park2, Hosung Yoon3, Yun-Jung Park4, Chong-Hyeun Yoon1, Jin-Jung Choi5, Wan-Uk Kim6 and Chul-Soo Cho1, 1College of Medicine, Catholic University of Korea, Seoul, South Korea, 2Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, 3The Catholic University, Incheon, South Korea, 4The Catholic University of Korea, Suwon, South Korea, 5CHA University, Bundang CHA General Hospital, Seongnam, South Korea, 6St. Vincent's Hospital, Suwon, South Korea
Feasibility of Implementing a Lifestyle Intervention and Its Effects on Metabolic Parameters and Adipokines in Overweight and Obese Patients with Systemic Lupus Erythematosus
Nehal Shah1, Amy D. Rickman2, Anne E. Mishler2, Nicole L. Wilson3, John M. Jakicic2, Susan Manzi4 and Amy H. Kao4, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, PA, 3W Penn Allegheny Health System, Pittsburgh, PA, 4Allegheny Singer Research Institute, Pittsburgh, PA
Renal Mir-150 As Potential Biomarker of Chronicity in Lupus Nephritis
Hua Zhou1, Sarfaraz A. Hasni2, Mayank Tandon1, Ilias Alevizos1, Howard A. Austin3, James E. Balow3 and Gabor G. Illei1, 1NIDCR, Bethesda, MD, 2NIH/NIAMS, Bethesda, MD, 3NIH/NIDDK, Bethesda, MD
Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus.  Clinical and Immunologic Associations
Ana-Maria Orbai1, Hong Fang1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago
Predictors of Earlier Time to Renal Failure Among Those with Biopsy-Proven Lupus Nephritis
Alí Duarte-García1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD
Do Active Lupus Patients Continue to Improve At 12 Months by Systemic Lupus Erythematous Disease Activity Index 2000 Responder Index 50 (SRI-50)?
Zahi Touma1, Murray B. Urowitz1, Dominique Ibanez1, Shahrzad Taghavi-Zadeh1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON
Lupus Disease Activity Does Not Improve Significantly in One System and Worsen in Another System
Zahi Touma1, Dafna D. Gladman2, Dominique Ibanez1, Shahrzad Taghavi-Zadeh1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON
Low Placebo Responses and Clinical Components of the Biomarkers of Lupus Disease (BOLD) Study May Provide Useful Insights for SLE Clinical Trial Design
Sudhakar T. Sridharan1, T. Zhou1, F. Immermann1, M. Lehmann1, J.L. Masferrer1, M. Honczarenko1, J.C. Rawdon2, J.A. James2 and J.T. Merrill2, 1Pfizer Inc, Collegeville, PA, 2Oklahoma Medical Research Foundation, Oklahoma City, OK
Frequency and Characteristics of Prolonged Remission in Systemic Lupus Erythematosus
Amanda J. Steiman1, Murray B. Urowitz1, Dominique Ibanez1, Anjali Papneja2 and Dafna D. Gladman3, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON
Comparison of the SF-36 Vs. Lupus Qol in Measuring Health-Related Quality of Life in Systemic Lupus Erythematosus Women with and without Activity
Claudia Mendoza-Pinto1, Mario Garcia-Carrasco Sr.1, Socorro Mendez-Martinez1, Oscar Pazarán1, Mario H. Cardiel2 and Aurelio Lopez-Colombo3, 1HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Hospital, Morelia, Mexico, 3Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Cognitive Dysfunction and Diffusion Tensor Imaging in Systemic Lupus Erythematosus
Elizabeth Kozora1, Aziz Ulug2, Doruk Erkan3, Glendalee Ramon3, An Vo4, Robert Zimmerman5, Emily Duggan1, JoAnn Vega3, Christopher Filley6 and Michael D. Lockshin3, 1National Jewish Health, Denver, CO, 2The Feinstein Institute for Medical Research, Manhasset, NY, 3Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 4The Feinstein Institute for Medical Reearch, Manhasset, NY, 5Weill Cornell Medical College, New York, NY, 6University of Colorado School of Medicine, Aurora, CO
Impaired Responses to Aspirin in Patients with Systemic Lupus Erythematosus: The Role of Inflammation and Oxidative Stress
Vivian K. Kawai1, Ingrid B. Avalos2, Annette M. Oeser1, John A. Oates1, Ginger L. Milne1, Cecilia P. Chung3 and C. Michael Stein1, 1Vanderbilt University, Nashville, TN, 2Harvard University, Boston, MA, 3Vanderbilt Medical Center, Nashville, TN
Infection As a Predictor of Organ System Damage Accrual and/or Death in Systemic Lupus Erythematosus
Amanda Eudy1, Deanna Hill2, Qinggong Fu2, Hong Fang3 and Michelle Petri3, 1UNC Chapel Hill, Chapel Hill, NC, 2GlaxoSmithKline, Collegeville, PA, 3Johns Hopkins University School of Medicine, Baltimore, MD
Low Prevalence of Use of ACEI/ARBS and Lipid Lowering Agents In African American(AA) SLE Patients
Asha Thomas, Madhu-Kalyan Pendurthi and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS
Population Pharmacokinetics of Sifalimumab, An Investigational Anti-Interferon-á Monoclonal Antibody, in Systemic Lupus Erythematosus Patients
Rajesh Narwal, Lorin Roskos, Wendy White, Warren Greth and Gabriel Robbie, MedImmune, Gaithersburg, MD
Do Race/Ethnicity and Geography Affect Outcomes in An Inception Cohort of Patients with Systemic Lupus Erythematosus Followed for At Least 5 Years?
D. D. Gladman1, Murray B. Urowitz1, Dominique Ibanez1, Nicole Anderson1 and Systemic Lupus International Collaborating Clinics (SLICC)2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto, ON
Microstructural Abnormalities in White and Deep Gray Matter Visualized within the First Year of Diagnosis in Adolescents with SLE: A Pilot Magnetization Transfer Imaging Study
Eyal Muscal1, Elfrides Traipe1, Elisabeth Wilde1, Douglas R. Bloom1, Barry L. Myones1, Zili D. Chu1, Robin L. Brey2 and Jill Hunter1, 1Baylor College of Medicine, Houston, TX, 2UTHSCSA, San Antonio, TX
Lupus and Body Image: An Intervention That Works
Meenakshi Jolly1, Kristin Peters2, Rachel A. Mikolaitis1, Kali Evans-Raoul3, Thomas F. Cash4 and Joel A. Block1, 1Rush University Medical Center, Chicago, IL, 2University of Missouri Health Care, Columbia, MO, 3The Image Studios, Chicago, 4Old Dominion University, Norfolk, VT
Clinical-Pathological Correlates of Proliferative Lesions in Lupus Nephritis
Claire Barber1, Murray B. Urowitz2, Dafna D. Gladman3, Joan E. Wither4, Carolina Landolt-Marticorena2, Heather Reich5, Wendy Lou6, Jiandong Su7, Jonathan Yip8, Gan Qian6, David Thomas9, Samih Nasr10, Rohan John8, Ellie Aghdassi8 and Paul R. Fortin7, 1Mount Sinai Hospital, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON, 4Toronto Western Research Institute, University Health Network, Toronto, ON, 5The Toronto Western Hospital, Toronto, ON, 6Dalla Lana School of Public Health, Toronto, ON, 7Toronto Western Hospital, Toronto, ON, 8University Health Network, Toronto, ON, 9Nephrocor, Long Island, NY, 10Division of Anatomic Pathology, Mayo Clinic, Rochester
Chronicity Index, Especially Glomerular Sclerosis, Is An Independent Predictor of Renal Response Following Immunosuppressive Treatment in Patients with Lupus Nephritis
Dong-Jin Park1, Sung-Ji Lee1, Tae-Jong Kim2, Yong-Wook Park2 and Shin-Seok Lee1, 1Chonnam National University Medical School, Gwangju, South Korea, 2Chonnam National University Medical School and Hospital, Gwangju, South Korea
Asian Ethnicity Is Associated with Increased Disease Severity in An Urban Australian SLE Cohort
Alberta Y. Hoi, Vera Golder and Eric F. Morand, Monash University, Melbourne, Australia
Incidence and Prevalence of Systemic Lupus Erythematosus in Buenos Aires, Argentina: A 11 Years Health Management Organization Based Study
Soledad M. Valeiras1, Martin F. Marchese1, Alejandro S. Talani1, Nicolas L. Avellaneda1, Alvaro Etchepare1, Patricio Etchepare1, Maria S. Plou1 and Enrique R. Soriano2, 1Instituto Universitario, Escuela de Medicina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Long-Term Outcome of Lupus Nephritis in Asian Indians Using Standard Therapy
Varun Dhir, Amita Aggarwal, Able Lawrence, Vikas Agarwal and Ramnath Misra, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India
Soluble Form of Herpesvirus Entry Mediator (HVEM) Is Elevated in Sera of Active Collagen-Vascular Diseases and Might Be a New Biomarker of Disease Activity
Satoko Arai, Kazuhiro Kurasawa, Harutsugu Okada, Takayoshi Ohwada, Reika Maezawa and Takeshi Fukuda, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan
Utility of IFN-á As Biomarker in Central Neuropsychiatric Involvement in SLE
Hilda Fragoso-Loyo, Yemil Atisha-Fregoso, Carlos Nuñez-Alvarez, Luis LLorente-Peters and Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico
Peripheral Arterial Disease in Systemic Lupus Erythematosus
Jose-Gabriel Erdozain1, Irama Villar2, Javier Nieto2, María-Victoria Egurbide2 and Guillermo Ruiz-Irastorza2, 1Hospital de Mendaro, Mendaro, Spain, 2Hospital de Cruces, UPV/EHU, Barakaldo, Spain
Characteristics of Disease Activity and Organ System Involvement in a Cohort of patients with Systemic Lupus Erythematosus Followed for More Than One Year
Marta Mosca1, Chiara Tani2, Linda Carli1, Grazia Maria Rizzelli1, Rossella Neri1, Antonio Tavoni3, Anna d'Ascanio4 and Stefano Bombardieri4, 1University of Pisa, Pisa, Italy, 2University of Pisa, Italy, 3Via Roma 67, Pisa, Italy, 4Rheumatology Unit, Pisa, Italy
Medication Impact on Gene Expression Patterns May Depend on Biologic Subgroups in the Biomarkers of Lupus Disease (BOLD) Study
Margot O'Toole1, Ying Zhang1, Attila Seyhan1, Frederick W. Immermann2, Andrew A. Hill3, Padmalatha S. Reddy3, Sudhakar T. Sridharan2, Monique Lehmann2, Jaime L. Masferrer4, Tianhui Zhou2, William M. Mounts3, Maryann Whitley3, Terry Walker1, Stan Kamp5, Judith A. James6, Marek Honczarenko1 and Joan T. Merrill7, 1Pfizer, Cambridge, MA, 2Pfizer Inc, Collegeville, PA, 3Pfizer, Cambridge, 4Pfizer Inc, Cambridge, MA, 5Oklahoma Medical Research Fund, Oklahoma City, 6Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 7Oklahoma Medical Research Foundation, Oklahoma City, OK
Treatment Regimens of Patients Enrolled in the Lupus Clinical Trials Consortium (LCTC)
Alana B. Levine1, Doruk Erkan2, Jill P. Buyon3 and Michael D. Lockshin2, 1Hospital for Special Surgery, New York, NY, 2Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 3NYU School of Medicine, New York, NY
Hydroxychloroquine-Induced Hyperpigmentation in Patients with Systemic Lupus Erythematosus. A Series of 23 Cases
Moez Jallouli, C. Francès, Jean-Charles Piette, Du Le Thi Huong, M. Miyara, D. Saadoun, A. Mathian, J. Haroche, C. De Gennes, G. Leroux, C. Chapelon, Bertrand Wechsler, Patrice Cacoub, Zahir Amoura and Nathalie Costedoat-Chalumeau, CHU Pitié-Salpêtrière, Paris, France
Response to Hydroxychloroquine in Japanese Patients with Cutaneous Lupus Erythematosus Using the Cutaneous Lupus Erythematosus Disease Area and Severity Index
Naoto Yokogawa1, Takaharu Ikeda2, Kyo Aizawa3, Akiko Tanikawa4, Masayuki Amagai4, Yukihiko Kato5, Yoko Momose6, Satoru Arai6, Hikaru Eto6, Fukumi Furukawa2 and Japanese Hydroxychloroquine Study Group7, 1Tokyo Metropolitan Tama Medical Center, Section of Rheumatology, Tokyo, Japan, 2Wakayama Medical University, Department of Dermatology, Wakayama, Japan, 3Sanofi-Aventis K.K. Biostatistics & Programming, Tokyo, Japan, 4Keio University School of Medicine, Department of Dermatology, Tokyo, Japan, 5Tokyo Metropolitan Tama Medical Center, Section of Dermatology, Tokyo, Japan, 6St. Luke's International Hospital, Department of Dermatology, Tokyo, Japan, 7Japan
SLE and Sickle Cell Disease (SCD) As Comorbid Conditions
Asha Thomas, Madhu Kalyan Pendurthi, Robert W. McMurray and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS
Pregnancy Outcomes and Fetal Complications in Patients with Systemic Lupus Erythematosus:a Retrospective Analysis in Korea
Eun-Jung Park1, Jiwon Hwang1, Jaejoon Lee2, Joong Kyong Ahn3, Chan Hong Jeon4, Hoon-Suk Cha1 and Eun-Mi Koh1, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, 3Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Soonchunhyang University College of Medicine, Bucheon, South Korea
Relationship Between Age of Onset and Clinical Profile In Systemic Lupus Erythematosus Patients
Julia Martínez-Barrio, Juan G. Ovalles, Francisco J. López-Longo, Inmaculada de la Torre, Lina Martínez-Estupiñán, Juan C. Nieto and Luis Carreño, Gregorio Marañón Hospital, Madrid, Spain
Serum Cystatin C Is Affected by Inflammation and Renal Dysfunction in Patients with Systemic Lupus Erythematosus
Christine LY Chew1, Awal Al-M Husain1, Philip Pemberton2, Sahena Haque1, Allen Yates2 and Ian N. Bruce3, 1University of Manchester, Manchester, United Kingdom, 2Manchester Royal Infirmary, Manchester, United Kingdom, 3A, Manchester, United Kingdom
Factors Associated with Belimumab Treatment Benefit: Results From Phase 3 Studies in Patients with Systemic Lupus Erythematosus
R.F. van Vollenhoven1, M. Petri2, R. Cervera3, C. Kleoudis4, Z.J. Zhong5, D. Roth6, W. Freimuth5 and BLISS-52 and BLISS-76 Study Groups7, 1The Karolinska Institute, Stockholm, Sweden, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Hospital Clinic, Barcelona, Spain, 4GlaxoSmithKline, Durham, NC, 5Human Genome Sciences, Inc., Rockville, MD, 6GlaxoSmithKline, King of Prussia, PA, 7Multicenter
Towards a Quantitative Assessment of Renal Biopsies for Lupus Nephritis
Siddharth S. Samsi1, Brad H. Rovin2, Sara Cole3, Don Stredney1 and Wael N. Jarjour4, 1Ohio Supercomputer Center, Columbus, OH, 2Ohio State University Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Ohio State University, Columbus, OH
The Relationship Between Pain Coping Skills and Pain, Fatigue, Mood, and Lupus Activity
Preethi Kurakula, Tamara J. Somers, Lisa G. Criscione-Schreiber, Francis J. Keefe and Megan E. B. Clowse, Duke University Medical Center, Durham, NC
Memory Complaints in Lupus Patients: Relationship to Lupus Activity, Symptoms, Quality of Life, Psychological Distress, and Coping
Megan E. B. Clowse1, Lisa G. Criscione-Schreiber1, Meenakshi Jolly2, Francis J. Keefe1 and Tamara J. Somers1, 1Duke University Medical Center, Durham, NC, 2Rush University Medical Center, Chicago, IL
The Leiden Neuropsychiatric Systemic Lupus Erythematosus Clinic; Establishing Clinical Phenotypes
E. Zirkzee, G. Steup-Beekman, H. Middelkoop, E. Bollen, N. Van der Wee, E. Baptist, R. Van der Mast, M. Huisman, J. Luyendijk, M. Van Buchem and T. Huizinga, Leiden University Medical Center, Leiden, Netherlands
Limited Value of Soluble Urokinase Plasminogen Activator Receptor As a Disease Activity Marker in Patients with Systemic Lupus Erythematosus
Helena Enocsson, Jonas Wettero, Thomas Skogh and Christopher Sjowall, Linkoping University, Linkoping, Sweden
Caregiver Burden Is Associated with Worse Dyadic Relationship and Health Outcomes in Lupus
Amita Thakkar, Rachel A. Mikolaitis, Joel A. Block and Meenakshi Jolly, Rush University Medical Center, Chicago, IL
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.